|
| 移植肾受者的骨质疏松研究进展 |
| Research progress of osteoporosis in renal transplant recipients |
| |
| DOI：10.3969/j.issn.1006.7108.2015.12.021 |
| 中文关键词: 骨质疏松 移植肾受者；骨密度；糖皮质激素；维生素D 膦酸盐类药物 |
| 英文关键词:Osteoporosis Renal allograft recipients Bone mineral density Glucocorticoids Vitamin D Bisphosphonates |
| 基金项目: |
|
| 摘要点击次数: 811 |
| 全文下载次数: 771 |
| 中文摘要: |
| 骨质疏松症是肾移植患者常见的并发症之一，严重影响到移植肾受者的生活质量，造成移植肾受者骨量减低的原因是多方面的，其中重要的原因之一就是激素的长期应用。由于肾移植患者须合用糖皮质激素及其他免疫抑制剂以控制症状,但 其最佳剂量既可最大地控制患者病情，又可尽可能小地减少对肾移植受者骨量产生影响仍有待进一步地研究与统一。为了尽可能地改善移植肾受者的骨量以提高其生存质量，有多项研究资料表明，维生素D与膦酸盐类药物可能会改善肾移植受者的 骨密度。 |
| 英文摘要: |
| Osteoporosis is a common complication in renal transplantation patients. It seriously affects the quality of life in renal allograft recipients. The cause of bone mass loss in graft recipients is various. One of the important reasons is the long-term application of hormones. Renal transplant patients have to be treated with corticosteroids and other immunosuppressive agents to control the symptoms. However, the optimal dose that not only can control the patient’s condition, but also can reduce its influence to bone mass in renal transplant recipients, remains to be studied and integrated. A number of research data show that both vitamin D and bisphosphonates may improve the bone mineral density in the renal transplant recipients, resulting in improved bone mass and the quality of life in the renal allograft recipients. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |